CClinicalTrials.gg
RecruitingNCT07196501Updated Jul 24, 2026

A Study to Evaluate the Maintenance Effect of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)

A Phase 3 interventional study of NBI-1065845 and Placebo in Major Depressive Disorder, sponsored by Neurocrine Biosciences. Recruiting at 60 sites in 11 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-24.

Sponsored by Neurocrine Biosciences · Phase 3, Interventional, and Treatment

Phase
Phase 3
Study type
Interventional
Enrollment
550
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The primary objective of this study is to evaluate the efficacy of NBI-1065845 compared with placebo as an adjunctive treatment in delaying relapse of depressive symptoms (maintenance of effect) in participants with MDD.

02

Conditions studied

  • Major Depressive Disorder

Keywords

  • Major Depressive Disorder
  • MDD
  • NBI-1065845
03

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Participant has a primary diagnosis of recurrent MDD (moderate or severe) or persistent depressive disorder.
  • Participant has had an inadequate response to oral antidepressant treatments in the current episode of depression.
  • Participant must have been taking oral antidepressants for at least 8 weeks and is willing to continue the same oral antidepressants at the same dose and frequency of administration throughout participation in the study.
  • Total Hamilton Depression Rating Scale-17 Item (HAM-D17) score ≥22 at screening and at study baseline (Day 1).
  • Willing and able to comply with all study procedures and restrictions in the opinion of the investigator.

Key Exclusion Criteria:

  • A current or prior psychiatric disorder diagnosis in the last 1 year that was the primary focus of treatment other than MDD.
  • Are considered by the investigator to be at imminent risk of suicide or injury to self or others.
  • Participants depressive symptoms have previously demonstrated nonresponse to electroconvulsive therapy (ECT) in the current major depressive episode.

Note: Other protocol-defined Inclusion and Exclusion criteria may apply.

04

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
550 participants (estimated)

Study arms

  • Experimental
    Open-label Treatment Period: NBI-1065845

    Participants will be treated with NBI-1065845 during the open-label treatment period.

    Drug: NBI-1065845

  • Experimental
    Randomized Double-blind Maintenance Period: NBI-1065845

    Participants will be randomized to receive NBI-1065845 during the randomized double-blind maintenance period.

    Drug: NBI-1065845

  • Experimental
    Randomized Double-blind Maintenance Period: Placebo

    Participants will be randomized to receive matching placebo during the randomized double-blind maintenance period.

    Drug: Placebo

Interventions

  • DrugNBI-1065845

    Oral tablet

  • DrugPlacebo

    Oral tablet

05

What researchers measure

Primary outcomes

  1. Time from Randomization to Relapse

    Time frame: From randomization to the earliest of relapse or end-of study (up to approximately 32 months)

06

Study locations

57 of 60 sites recruiting
  • Neurocrine Clinical Site
    Oceanside, California 92056, United States
    Recruiting
  • Neurocrine Clinical Site
    Orange, California 92868, United States
    Recruiting
  • Neurocrine Clinical Site
    San Jose, California 95124, United States
    Recruiting
  • Neurocrine Clinical Site
    New Haven, Connecticut 06520, United States
    Recruiting
  • Neurocrine Clinical Site
    Miami Gardens, Florida 33014, United States
    Recruiting
  • Neurocrine Clinical Site
    Orlando, Florida 32803, United States
    Recruiting
  • Neurocrine Clinical Site
    Palm Bay, Florida 32905, United States
    Recruiting
  • Neurocrine Clinical Site
    Tampa, Florida 33629, United States
    Recruiting
  • Neurocrine Clinical Site
    Iowa City, Iowa 52242, United States
    Recruiting
  • Neurocrine Clinical Site
    Marrero, Louisiana 70072, United States
    Recruiting
  • Neurocrine Clinical Site
    O'Fallon, Missouri 63368, United States
    Recruiting
  • Neurocrine Clinical Site
    Albuquerque, New Mexico 87109, United States
    Recruiting
  • Neurocrine Clinical Site
    Glen Oaks, New York 11004, United States
    Recruiting
  • Neurocrine Clinical Site
    Charlotte, North Carolina 28211, United States
    Recruiting
  • Neurocrine Clinical Site
    Edmond, Oklahoma 73013, United States
    Recruiting
  • Neurocrine Clinical Site
    Oklahoma City, Oklahoma 73112, United States
    Recruiting
  • Neurocrine Clinical Site
    Philadelphia, Pennsylvania 19104, United States
    Recruiting
  • Neurocrine Clinical Site
    Austin, Texas 78712, United States
    Active, not recruiting
  • Neurocrine Clinical Site
    Bellaire, Texas 77401, United States
    Recruiting
  • Neurocrine Clinical Site
    Friendswood, Texas 77546, United States
    Terminated
  • Neurocrine Clinical Site
    Stafford, Texas 77477, United States
    Recruiting
  • Neurocrine Clinical Site
    Wichita Falls, Texas 76309, United States
    Recruiting
  • Neurocrine Clinical Site
    Draper, Utah 84020, United States
    Recruiting
  • Neurocrine Clinical Site
    Roanoke, Virginia 24018, United States
    Recruiting
  • Neurocrine Clinical Site
    Carlton, Victoria 3053, Australia
    Recruiting
  • Neurocrine Clinical Site
    Melbourne, Victoria 3004, Australia
    Recruiting
  • Neurocrine Clinical Site
    Parkville, Victoria 3050, Australia
    Recruiting
  • Neurocrine Clinical Site
    Sofia, 1303, Bulgaria
    Recruiting
  • Neurocrine Clinical Site
    Sofia, 1408, Bulgaria
    Recruiting
  • Neurocrine Clinical Site
    Sofia, 1510, Bulgaria
    Recruiting
  • Neurocrine Clinical Site
    Sofia, 1680, Bulgaria
    Recruiting
  • Neurocrine Clinical Site
    Calgary, Alberta T2N 2T9, Canada
    Recruiting
  • Neurocrine Clinical Site
    North Vancouver, British Columbia V7P 2T4, Canada
    Recruiting
  • Neurocrine Clinical Site
    Kingston, Ontario K7L 4X3, Canada
    Recruiting
  • Neurocrine Clinical Site
    Sherbrooke, Quebec J1L 0H8, Canada
    Recruiting
  • Neurocrine Clinical Site
    Toronto, M5H 1A1, Canada
    Recruiting
  • Neurocrine Clinical Site
    Tallinn, 10138, Estonia
    Recruiting
  • Neurocrine Clinical Site
    Tallinn, 11315, Estonia
    Recruiting
  • Neurocrine Clinical Site
    Tartu, 50417, Estonia
    Recruiting
  • Neurocrine Clinical Site
    Milan, 20127, Italy
    Withdrawn
  • Neurocrine Clinical Site
    Roma, 168, Italy
    Recruiting
  • Neurocrine Clinical Site
    Rome, 168, Italy
    Recruiting
  • Neurocrine Clinical Site
    Torino, 10126, Italy
    Recruiting
  • Neurocrine Clinical Site
    Bialystok, 15-879, Poland
    Recruiting
  • Neurocrine Clinical Site
    Bydgoszcz, 85-794, Poland
    Recruiting
  • Neurocrine Clinical Site
    Gdansk, 80-283, Poland
    Recruiting
  • Neurocrine Clinical Site
    Belgrade, 11000, Serbia
    Recruiting
  • Neurocrine Clinical Site
    Kovin, 26220, Serbia
    Recruiting
  • Neurocrine Clinical Site
    Kragujevac, 34000, Serbia
    Recruiting
  • Neurocrine Clinical Site
    Ansan-si, Gyeonggi-do 15355, South Korea
    Recruiting
  • Neurocrine Clinical Site
    Seoul, 02841, South Korea
    Recruiting
  • Neurocrine Clinical Site
    Seoul, 06351, South Korea
    Recruiting
  • Neurocrine Clinical Site
    Seoul, 3181, South Korea
    Recruiting
  • Neurocrine Clinical Site
    Alcorcón, Madrid 28922, Spain
    Recruiting
  • Neurocrine Clinical Site
    Barcelona, 08025, Spain
    Recruiting
  • Neurocrine Clinical Site
    Barcelona, 08035, Spain
    Recruiting
  • Neurocrine Clinical Site
    Keelung, 204, Taiwan
    Recruiting
  • Neurocrine Clinical Site
    Taipei, 10449, Taiwan
    Recruiting
  • Neurocrine Clinical Site
    Taipei, 110, Taiwan
    Recruiting
  • Neurocrine Clinical Site
    Taipei, 11217, Taiwan
    Recruiting
07

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT07196501
Lead sponsor
Neurocrine Biosciences
Responsible party
Sponsor
First posted
Sep 29, 2025
Start date
Aug 18, 2025
Primary completion
Jul 2028 (estimated)
Completion
Jul 2028 (estimated)
Last update
Jul 24, 2026

Study contacts

Neurocrine Medical Information Call Center
Contact
medinfo@neurocrine.com
1-877-641-3461
Clinical Development Lead
study director · Neurocrine Biosciences

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion